In earlier studies from this laboratory evidence was obtained for a physiological function of tissue factor pathway inhibitor (TFPI) as a regulator of hemostasis capable of preventing thrombotic complications that might otherwise result from exposure of blood to trace amounts of tissue factor (TF). However, it was not possible to conclude that the protective effect of TFPI stemmed solely from inhibition of factor VIIa/TF catalytic activity, since TFPI neutralizes stoichiometric amounts of factor Xa in forming an inhibited factor Xa/TFPI/factor VIIa/TF complex. Therefore, we examined the effects of immunodepletion of TFPI on the extent of coagulation initiated in rabbits by exposure to factor Xa and phospholipid in the absence of TF. In one experimental approach, factor Xa was generated endogenously with the factor X-activating fraction of Russell's viper venom (0.33 /xg/kg) in rabbits receiving an infusion of phosphatidylcholine/phosphatidylserine (PCPS) vesicles, 1 nig/kg over 2 hours. In a second approach, rabbits were injected with a complex of factor Xa (0.75 jug/kg) and PCPS (12.5 yug/kg). In contrast with the observed sensitization of TFPI-depleted rabbits to TF-induced coagulation, TFPI-depleted rabbits were not sensitized to coagulation initiated by factor Xa and phospholipid in the absence of TF. These data support the conclusion that the physiological function of TFPI in regulating TF-dependent coagulation stems primarily from its ability to inhibit factor VIIa/TF catalytic activity. (Arterioscler Thromb. 1993;13:1551-1557.)
T issue factor pathway inhibitor (TFPI) is a Kunitztype protease inhibitor that has been shown in vitro to function effectively as an inhibitor of factor Vila/tissue factor (TF) catalytic activity in a two-step feedback reaction requiring the participation of generated factor Xa. 1 -2 In the first step, factor Xa binds to TFPI with resultant neutralization of factor Xa. In the second step, the factor Xa/TFPI complex binds to and inhibits the catalytic activity of factor VIIa/TF complexes. In recent in vivo studies from this laboratory, concentrations of TF too low to trigger intravascular coagulation in normal rabbits were found to induce substantial intravascular coagulation in rabbits immunodepleted of TFPI. 3 ' 4 These studies provided strong evidence for a physiological function of TFPI as a regulator of hemostasis capable of preventing thrombotic complications that might otherwise result from intravascular exposure of blood to trace amounts of TF. However, it was not possible to conclude from these studies that the protective effect of TFPI stemmed solely from inhibition of factor VIIa/TF catalytic activity, since in the process of such inhibition, TFPI also neutralized stoichiometric amounts of factor Xa. Although the total intravascular pool of TFPI is potentially capable of neutralizing only a small amount of Received June 15, 1993 ; revision accepted July 19, 1993 . factor Xa, 2 -5 it is noteworthy that in an earlier study from this laboratory factor X levels did not fall significantly in rabbits receiving a 4-hour infusion of TF that led to the consumption of almost 90% of circulating fibrinogen. 6 One may infer from such data that only small amounts of factor Xa need to be generated to sustain extensive TF-induced intravascular coagulation.
These considerations prompted us to perform experiments to test whether the factor Xa neutralizing capacity of TFPI is itself of physiological significance, ie, whether it can dampen intravascular coagulation induced independently of TF. In these experiments, the circulating blood of rabbits immunodepleted of plasma TFPI was exposed to factor Xa under two experimental conditions. In the first, the rabbits were injected with the factor X activator from Russell's viper venom (RVV-X) and infused with a suspension of phosphatidylcholine/phosphatidylserine (PCPS) vesicles. In the second, rabbits were injected with a formed factor Xa/PCPS/Ca 2+ complex. The results of these studies supported the conclusion that the regulatory role of TFPI in hemostasis stems primarily from its ability to inhibit factor VIIa/TF catalytic activity.
Richmond, Calif. Rabbit brain preparations (cephalin, thromboplastin, and acetone powder), RVV, bovine serum albumin (BSA), normal goat serum, endotoxin, and phospholipids from bovine brain were obtained from Sigma, St Louis, Mo. Octyl glucopyranoside and rabbit serum albumin were obtained from Calbiochem, La Jolla, Calif. Benzamidine was purchased from Aldrich Chemical Co, Milwaukee, Wis. Other chemicals, reagent grade or better, were purchased from Sigma or Fisher Scientific, Springfield, NJ.
Purified Coagulation Proteins
Human factor X was purified and activated with insolubilized RVV as described previously. 7 Recombinant human factor Vila was from Novo-Nordisk, Gentofte, Denmark. Rabbit TFPI was isolated from rabbit plasma as described previously.
8 Rabbit brain TF was purified 9 and reconstituted into phospholipid vesicles (60% phosphatidylcholine/40% phosphatidylserine [60% PC/40% PS]) by using octyl glucoside. 10 PCPS vesicles for infusion were prepared by the same procedure without the addition of TF apoprotein.
Anti-TFPI Immunoglobulin G
The goat polyclonal antibody to rabbit TFPI used in these experiments has been described in detail elsewhere. 3 ' 4 Twelve micrograms anti-rabbit TFPI immunoglobulin G (IgG) neutralized -5 0 % of the TFPI activity in 1 mL rabbit plasma. Nonimmune control goat IgG was prepared similarly from serum obtained from normal goats.
One-Stage Clotting Assays
Pel-Freez pooled rabbit plasma or a pooled plasma prepared from blood obtained from 6 to 7 normal young rabbits was used as a reference plasma for coagulation assays. Human deficiency plasmas were collected from human donors or prepared by immunodepleting freshly collected plasma obtained from normal volunteers. Test plasmas were diluted in cold tris(hydroxymethyl)aminomethane (Tris)-buffered saline (TBS; 0.05 mol/L Tris-HCl, pH 7.5, and 0.15 mol/L NaCl) containing 1 mg/mL BSA (TBS/BSA) and were clotted in duplicate. An automated coagulometer was used to measure clotting times (MLA Electra 700 or Lancer Coagulizer II).
In the first rabbit study with RVV-X, factor X activities were measured in a one-stage factor X assay with a human factor X-deficient plasma fortified with barium-adsorbed rabbit plasma (1:1) as substrate plasma. In the second study with a formed factor Xa/PCPS/Ca 2+ complex, a rabbit factor X-deficient substrate plasma, prepared by immunoabsorption of rabbit plasma with an immobilized monoclonal antibody to rabbit factor X, 11 was available in the laboratory and was substituted for the human factor X-deficient plasma. Test plasmas were assayed at a dilution of 1:20 in both factor X assays.
Factor V was measured in a one-stage assay with a human factor V-deficient substrate and a 1:100 or 1:200 dilution of rabbit plasma as test sample. Prothrombin was measured in a one-stage assay with a rabbit prothrombin-deficient substrate prepared by mixing equal parts of rabbit serum and barium-adsorbed rabbit plasma. The serum was prepared by clotting rabbit blood with 1% rabbit brain thromboplastin in a glass tube and dialyzing the resultant serum to remove Ca 2+ . For this assay the barium-adsorbed rabbit plasma was prepared from blood drawn from a rabbit given an intravenous injection of 100 /xg/kg endotoxin 24 hours earlier to boost plasma fibrinogen. Rabbit test plasmas were diluted 1:20 for the prothrombin assay. Fibrinogen was measured by the method of Gauss 12 using bovine thrombin (Dade, Miami, Fla).
TFPI Activity Assays
TFPI was measured in a two-stage capacity assay in which residual factor VIIa/TF activity was measured after the incubation of a test sample with factor Vila, TF, factor Xa, and Ca 2+ . 3 The incubation mixture contained a rabbit plasma test sample diluted to 0.4% to 1.6% plasma; a limiting concentration of reconstituted purified rabbit TF (2.5 ng/mL); a saturating concentration of recombinant human factor Vila (0.1 fjiglmV); human factor Xa (0.02 /xg/mL); and CaCl 2 (10 mmol/L) in a final volume of 75 /xL in TBS/BSA. After 30 minutes at room temperature, residual factor VIIa/TF activity was determined by its ability to activate factor X. A mixture (100 fi\J) containing human factor X (3.2 /xg/mL), Chromozym X (0.625 mg/mL), and CaCl 2 (5 mmol/L) was added to the sample wells. The amidolytic reaction was quenched after ~8 minutes by adding 30 /xL 50% acetic acid, and the absorbance was read at 405 nm in a microplate reader (Molecular Devices). PelFreez pooled normal rabbit plasma or a pooled plasma obtained from 6 to 7 normal rabbits was used as a reference plasma arbitrarily assigned an activity of 1 U TFPI/mL.
Venom Activity Assays
RVV-X was assayed by its ability to activate factor X essentially as described by Furie and Furie. 13 Dilutions of samples containing venom (50 /XL) were incubated with normal rabbit plasma (50 /xL) and 40% cephalin (50 /XL) for 2 minutes at 37°C. Clotting was initiated by the addition of 50 /xL of 25 mmol/L CaCl 2 . A 1-^.g/mL dilution of dialyzed, resuspended crude venom, which clotted the assay mixture in 10 seconds, was arbitrarily assigned a value of 1 U RVV-X activity. Since the factor V activator present in RVV (RVV-V) does not activate rabbit factor V, 14 RVV-V was assayed by its ability to activate factor V in human plasma essentially as described elsewhere.
1516
Purification of RVV-X RVV-X was purified ~18-fold with -5 1 % recovery from crude RVV by using the procedure of Kisiel et al 17 using benzamidine in all purification buffers. RVV-X (-79 kDa) was separated from RVV-V (-20 kDa) by gel filtration and was purified further by ion exchange chromatography. The protein concentrations of the venom fractions were estimated from their absorbance at 280 nm, assuming an extinction coefficient of 10 mg/mL (1% solution) with a 1-cm path=10.0. The final RVV-X preparation (28 mg) was essentially homogeneous with a trace contaminant migrating at -58 kDa, had a specific factor X-activating activity of 18 500 U/mg, and contained no measurable RVV-V activity.
Formation of Factor Xa/PCPS/Ca

2+
Complexes
Factor Xa was added to a suspension of PCPS vesicles in sterile saline containing 5 mmol/L CaCl 2 and 25 fig/mL rabbit albumin. The mixture was allowed to stand at room temperature for 5 to 10 minutes before use. Rabbit factor Xa that had been prepared for this purpose proved unstable on storage, and a human factor Xa preparation was used.
Animal Protocols
Female New Zealand rabbits (~2 kg) were used for these studies in protocols approved by the Animal Subjects Committee of the University of California, San Diego. Rabbits were given an intravenous injection of goat anti-rabbit TFPI IgG (10 mg/kg); control rabbits received 10 mg/kg nonimmune goat IgG. One control rabbit received no IgG. Two and one-half hours later, the rabbits received one of the following procoagulant challenges: (1) an intravenous injection of 0.5 to 1 mL RVV-X and an infusion over 2 hours of 1 mg/kg PCPS vesicles in 50 mL saline into the marginal vein of the opposite ear or (2) an intravenous injection of 1 mL of a formed factor Xa/PCPS/Ca 2+ complex. In each treatment group, data for analysis were obtained from 5 experimental animals and 5 control animals.
Blood samples (1 to 2 mL) were obtained from a marginal ear vein and processed as described earlier. 6 An initial sample was drawn before the injection of IgG for measurement of clotting factors, hematocrit, and platelet count. Additional samples were drawn at 30 minutes and 2 hours for measurement of platelets and clotting factors. Four to five additional samples were drawn after the animals were injected with either RVV-X/PCPS vesicles or the formed factor Xa/PCPS/Ca 2+ complex. For platelets and TFPI the levels measured on the sample obtained before the injection of IgG were assigned a value of 100%. For other clotting factors the levels measured in the sample drawn 2 hours after injection of IgG, ie, shortly before the procoagulant challenge, were assigned a value of 100%. Data are reported as mean±SEM of the 100% values.
Rectal temperature, measured as a sensitive indicator of exposure to material containing endotoxin, did not change significantly in any rabbit.
Results
Selection of the Dose of RVV-X
In a preliminary experiment, varying amounts of RVV-X, from 25 Mg/kg to 0.33 /xg/kg, were injected into rabbits to establish a dose that would cause only a minimal consumption of rabbit factor X comparable to that observed after the infusion of purified rabbit TF apoprotein reconstituted into PCPS vesicles in earlier studies (Reference 6 and B.J. Warn-Cramer, PhD, and S.L. Maki, MA, February 1993, unpublished data from the experiments reported in Reference 3). Injecting 25 /xg/kg RVV-X into a rabbit caused plasma factor X to fall dramatically to less than 5% within 20 minutes without an appreciable associated consumption of either prothrombin or fibrinogen (Fig 1) . Plasma factor V activity increased transiently. This appeared to reflect a minimal in vivo activation of factor V, since the in vitro addition of 0.5 iiglmL RVV-X to rabbit plasma (a concentration equivalent to that obtained after injecting 25 /ig/kg into a rabbit with a plasma volume of 50 mL/kg) had no effect on the factor V activity of the plasma as measured in our assay.
The injection of lower doses of RVV-X resulted in slower, less extensive, and continuing consumption of factor X over a 2-to 3-hour period (Fig 2) . For example, with a dose of 2 ;u,g/kg, factor X fell to 26% residual activity by 60 minutes. Factor V activity was elevated initially to 120% at 5 minutes but fell to 48% activity by 60 minutes (Table) . Only a modest fall in plasma prothrombin level and essentially no consumption of fibrinogen were measurable at 1 hour with any dose of RVV-X injected (Table) .
On the basis of the data shown in the Table, a dose of 0.33 /xg/kg RVV-X was selected as the dose initiating factor X consumption closest to that observed in our earlier experiments with the infusion of TF. In those experiments the TF was reconstituted in phospholipid vesicles containing 60% PC/40% PS. Therefore, it was decided that the injection of the RVV-X should be followed by an infusion of 60% PC/40% PS vesicles (1 mg/kg) in 50 mL saline over 2 hours to provide the equivalent of the amount of PCPS infused in experiments with TF. RW-X indicates factor X activator from Russell's viper venom; FX, factor X; and FV, factor V. Activity is expressed as a percentage of the activity measured in the sample collected before administration of RW-X. Values for the 1 > i g/kg and 0.33 /xg/kg doses represent results from two rabbits; one rabbit was used for each of the other three doses.
Effect of RVV-X and PCPS Infusion in TFPI-Depleted Rabbits
As in earlier studies, 34 the injection of 10 mg/kg anti-rabbit TFPI IgG depressed plasma TFPI activity to -20% of the initial level for several hours (Fig 3) . Platelets fell initially and gradually returned to -75% of the starting level by 2 hours (Fig 4) . To allow the platelet level to stabilize in the animals given anti-TFPI IgG, the administration of RVV-X and the PCPS infusion were delayed for 2lA hours after the injection of the IgG in both experimental and control animals.
Mean factor X levels fell to -7 5 % of the initial level ( Fig 5A) and mean factor V levels fell to -7 0 % of the initial level (Fig 5B) by 2 hours after the RVV-X injection both in rabbits receiving anti-TFPI IgG and in controls. Only minimal, if any, changes in the levels of prothrombin, fibrinogen, and platelets were observed (Fig 5C, 5D, and Fig 4, respectively) . Thus, immunodepletion of plasma TFPI failed to sensitize the rabbits to intravascular coagulation initiated by the fluid-phase generation of factor Xa in the presence of infused PCPS vesicles.
The factor X measurements in this study were made with a factor X assay that used a substrate containing human factor X-deficient plasma. It has since been shown that an assay that uses a rabbit factor X-deficient substrate is needed to obtain absolute values for rabbit plasma factor X activity. 11 Therefore, although the above factor X data were expressed as a percent of an initial level, sequential plasma samples obtained from two rabbits were assayed again with a rabbit factor X-deficient substrate. It was reassuring to confirm that the time course and extent of fall in plasma factor X levels after RVV-X were the same with the assay that used a rabbit factor X-deficient substrate (data not shown).
Effect of Administration of Formed Factor Xa/PCPS Complexes
Because of the above negative data, a second study was performed to determine the effect of immunodepletion of plasma TFPI on the ability of a formed complex of factor Xa/PCPS to induce intravascular coagulation. An evaluation of the ability of rabbit TFPI to neutralize such a complex in vitro was included in this study because the rate of inhibition of human factor Xa by a human TFPI preparation is reported to be slowed in the presence of cephalin and Ca 2+ . 18 In four experiments in which two rabbit TFPI preparations and two phospholipid preparations were used, the presence of phospholipid and Ca 2+ in reaction mixtures accelerated rather than slowed the rate at which a partially purified rabbit TFPI preparation neutralized human factor Xa amidolytic activity. The data from one such experiment are shown in Fig 6. These data, which demonstrated that rabbit TFPI had enhanced ability to neutralize factor Xa/PCPS in vitro, substantiated the need for in vivo data on the possible role of TFPI as a modulator of human factor Xa/PCPS-induced intravascular coagulation.
In preliminary experiments, complexes formed of various combinations of factor Xa and PCPS were injected into rabbits to select an appropriate combination for the study. Data from two combinations are shown in Fig 7 to illustrate that increasing the PCPS from 12.5 /xg/kg to 50 /xg/kg in a complex containing 0.75 Atg/kg factor Xa markedly increased the ability of the complex to induce intravascular coagulation, as manifested by consumption of factor V and fibrinogen. This was of interest, since with an assumed K d of 10" 6 to 0 2 4 6 8 Incubation (min) FIG 6 . Line graph showing the rate of neutralization of human factor Xa (Xa) amidolytic activity by rabbit tissue factor pathway inhibitor (TFPI) in the presence (•) or (o) absence of phosphatidylcholine/phosphatidylserine (PCPS). Twenty-five microliters factor Xa (0.3 /xg/mL) in tris(hydroxymethyl)aminomethane-buffered saline/ bovine serum albumin (TBS/BSA) containing 10 mmol/L CaCI 2 with or without PCPS (10 MO/TIL) was added to individual wells of a microtiter plate. An equal volume of a preparation containing ~22 /xg/mL rabbit TFPI in TBS/ BSA was added to the wells. After standing at room temperature for the times indicated, 50 /xL Chromozym X (1.25 mg/mL) was added, and the amidolytic activity of the residual factor Xa was determined by following the absorbance change at 405 nm. The 100% value shown at zero time represents the amidolytic activity of a mixture in which TBS/BSA containing no rabbit TFPI was added to wells. Control values are the mean of the activity in duplicate wells. Other values represent activity in a single well.
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-7 , i9 -2i >95% of the factor Xa should be bound to the vesicles even at the lower concentration of PCPS. Since the goal was to determine whether immunodepletion of TFPI sensitized rabbits to factor Xa/PCPS complexinduced coagulation, the combination of 0.75 tig/kg factor Xa and 12.5 xig/kg PCPS was selected for the experiments.
The immunodepleted rabbits did not differ from the control rabbits in the extent of fall in plasma levels of factor V, prothrombin, fibrinogen (Fig 8B, 8C , and 8D, respectively), or platelets (data not shown) after the injection of a complex made from 0.75 /xg/kg factor Xa and 12.5 ^tg/kg PCPS. As in the RVV-X experiments, coagulation initiated with a formed factor Xa/phospholipid complex was not enhanced in TFPI-depleted rabbits. Two additional observations were of interest. The first was the finding that plasma factor X levels fell by -15% within 10 minutes in both control and immunodepleted rabbits after the injection of factor Xa/PCPS (Fig 8A) . This was surprising, since coagulation initiated by a factor Xa/PCPS complex should bypass the activation step of plasma factor X in coagulation. The second was the finding of a transient increase in plasma TFPI activity after the injection of a factor Xa/PCPS complex (Fig 3B) , an observation that was also noted after the injection of RVV-X (Fig 3A) .
Discussion
The experiments described were designed to extend earlier studies from this laboratory in which immunodepletion of plasma TFPI was shown to sensitize rabbits to substantial intravascular coagulation induced by concentrations of TF that were unable to trigger intravascular coagulation in normal rabbits. 3 ' 4 Whereas those studies provide convincing evidence for a physiological function of TFPI as a regulator of factor VIIa/TFinduced coagulation, they did not address the question of whether the ability of TFPI to neutralize stoichiometric amounts of factor Xa contributed to the protective effect of TFPI. We believed that this possibility could not be excluded a priori from the knowledge that the size of the pool of circulating factor X exceeds manyfold the size of the total intravascular pool of TFPI in rabbits. 5 This is because the defibrination resulting from extensive TF-induced intravascular coagulation in rabbits found in another study from this laboratory occurred with only a minimal consumption of plasma factor X. 6 Moreover, there were no previous data to evaluate whether neutralization of factor Xa activity by TFPI could dampen coagulation induced independently of TF, eg, the coagulation induced by small amounts of factor Xa associated with phospholipid from platelet fragments, which has been suggested as a cause for thrombosis after the administration of prothrombin complex concentrates. 22 The present data did not support a role for TFPI as a physiologically significant inhibitor of factor Xa. In contrast to our observations with TF-induced coagulation, 34 immunodepletion of TFPI failed to sensitize rabbits to coagulation induced by a combination of slow RVV-X-induced generation of factor Xa and an infusion of phospholipid. A combination that was unable to trigger significant coagulation in normal rabbits was also unable to trigger significant coagulation in TFPI-depleted rabbits.
Other data from the experiments with RVV-X-induced generation of factor Xa deserve comment. Aronson 23 reports that rabbits can be injected with a concentration of RVV-X that leads to rapid consumption of essentially all circulating plasma factor X with only a minimal fall in plasma levels of prothrombin and fibrinogen. Our data of Fig 1 confirm this observation . It is impressive that in vivo mechanisms exist for the neutralization and clearance of the very large amounts of factor Xa generated by RVV-X in the fluid phase.
It is also of interest that infusing 1 mg/kg PCPS vesicles into rabbits given a low dose of RVV-X (0.33 ;u,g/kg), which induced modest continuing consumption of factor X, did not appear to potentiate intravascular coagulation (Table and Fig 5) . Under our experimental conditions, a slow fluid-phase activation of as much as 25% of plasma factor X in the presence of the continuing entrance of PCPS vesicles into the circulation apparently could not lead to the formation of substantial prothrombinase activity.
This observation contrasts strikingly with the defibrination that can be induced in rabbits by an infusion of TF reconstituted in PCPS vesicles that causes only an insignificant fall in plasma factor X. 6 Therefore, we undertook the second part of the present study, in which we injected rabbits immunodepleted of TFPI with a formed factor Xa/PCPS complex. In our earlier experiments, 3 which demonstrate that immunodepleting plasma TFPI sensitizes rabbits to intravascular coagulation induced by a low concentration of TF, we infused a concentration of TF that failed to cause intravascular coagulation in normal control rabbits. Thus, a test of the hypothesis that TFPI-mediated inhibition of factor Xa generated on a PCPS vesicle containing TF contributed significantly to the protective effect of TFPI in this earlier study required selecting a factor Xa/PCPS combination (0.75 /xg/kg factor Xa and 12.5 fig/kg PCPS) that also failed to trigger intravascular coagulation in normal control rabbits. (If one assumes a rabbit plasma TFPI concentration similar to the 100 ng/mL concentration in human plasma, then the exogenous factor Xa injected in this complex was well below the stoichiometric inhibitory capacity of plasma levels of TFPI.) In contrast to the experiments with TF, immunodepletion of plasma TFPI failed to sensitize rabbits to the intravenous injection of this factor Xa/PCPS preparation (Fig 8) . This represents for us substantial indirect evidence that the protection TFPI afforded rabbits against TF-induced intravascular coagulation in our earlier experiments 34 stemmed primarily from inhibition of factor VIIa/TF catalytic activity and not from TFPI-mediated inhibition of factor Xa.
As reported by others, the concentration of phospholipid used to form factor Xa/PCPS complexes was crucial to the net coagulation-inducing effect of a limited concentration of factor Xa. 24 - 25 If a complex was formed with the same limited amount of factor Xa (0.75 Mg/kg) and a fourfold increased amount of PCPS (50 fig/kg) , then the complex triggered extensive intravascular coagulation in rabbits with normal levels of TFPI (Fig 7) . In this circumstance, normal levels of plasma TFPI could not protect against the substantial intravascular coagulation induced by a concentration of factor Xa that was well within the capacity of plasma TFPI to neutralize. Therefore, we felt that giving such a factor Xa/PCPS combination to TFPI-depleted animals would not test further the hypothesis that TFPI-mediated neutralization of factor Xa plays a significant role in the protection TFPI affords normal rabbits against coagulation induced by low concentrations of TF. Another finding of considerable interest to us was the unanticipated modest but rapid fall in plasma factor X levels that followed the injection of the 0.75 /xg factor Xa/12.5 p,g PCPS complex that produced only minimal, if any, evidence of intravascular coagulation (Fig 8A) . Accelerated clearance of plasma factor X after binding to phospholipid micelles was ruled out as a cause for this fall because we have found 26 that a bolus injection of 50 /tg/kg PCPS vesicles alone fails to induce a significant fall in plasma factor X. We are unaware of data that factor Xa/PCPS vesicles can directly activate factor X, and we believe that this fall in plasma factor X represents evidence of consumption of factor X induced by an indirect mechanism. Since the fall in plasma factor X occurred without delay and was similar in extent in both control and TFPI-depleted animals, one can eliminate a factor VIIa/TF-catalyzed activation of factor IX, factor X, or both as the mechanism.
In summary, the data reported here provide substantial evidence that neutralization of factor Xa by TFPI does not in itself play a significant role in the physiological function of TFPI as a regulator of TF-induced blood coagulation. The regulatory consequence of the interaction of TFPI with factor Xa appears to be limited to facilitating the formation of a quaternary factor Xa/ TFPI/factor VIIa/TF complex with inhibited catalytic activity.
